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Receptor-targeted liposome-
peptide-siRNA nanoparticles 
represent an efficient delivery 
system for MRTF silencing in 
conjunctival fibrosis
Cynthia Yu-Wai-Man1, Aristides D. Tagalakis2, Maria D. Manunta2, Stephen L. Hart2 & 
Peng T. Khaw1
There is increasing evidence that the Myocardin-related transcription factor/Serum response factor 
(MRTF/SRF) pathway plays a key role in fibroblast activation and that knocking down MRTF can lead to 
reduced scarring and fibrosis. Here, we have developed a receptor-targeted liposome-peptide-siRNA 
nanoparticle as a non-viral delivery system for MRTF-B siRNA in conjunctival fibrosis. Using 50 nM 
siRNA, the MRTF-B gene was efficiently silenced by 76% and 72% with LYR and LER nanoparticles, 
respectively. The silencing efficiency was low when non-targeting peptides or siRNA alone or liposome-
siRNA alone were used. LYR and LER nanoparticles also showed higher silencing efficiency than 
PEGylated LYR-P and LER-P nanoparticles. The nanoparticles were not cytotoxic using different 
liposomes, targeting peptides, and 50 nM siRNA. Three-dimensional fibroblast-populated collagen 
matrices were also used as a functional assay to measure contraction in vitro, and showed that MRTF-B 
LYR nanoparticles completely blocked matrix contraction after a single transfection treatment. In 
conclusion, this is the first study to develop and show that receptor-targeted liposome-peptide-siRNA 
nanoparticles represent an efficient and safe non-viral siRNA delivery system that could be used to 
prevent fibrosis after glaucoma filtration surgery and other contractile scarring conditions in the eye.
RNA interference (RNAi) is a promising therapeutic approach as it can be used to silence the expression of harm-
ful genes in a wide range of diseases1. Small interfering RNAs (siRNAs) are double-stranded RNA molecules 
20–25 nucleotides long that regulate gene expression by driving a target messenger RNA to degradation, thus 
leading to gene silencing2. Delivery of naked siRNAs is however unlikely to be effective as siRNAs do not cross 
cell membranes and are susceptible to degradation by RNAses. Viral delivery systems like adenoviral vectors have 
been used to deliver shRNAs but carry the risk of oncogenicity and immunogenicity3,4. As a result, there is now 
increasing interest in developing non-viral methods, in particular nanoparticles, as a safe and efficient siRNA 
delivery system5,6.
There is also growing interest in developing potential siRNA therapeutics in the eye. Different research groups 
are studying siRNA-based therapeutic strategies in herpetic stromal keratitis7, retinoblastoma8, and ocular 
inflammation9. The synthetic siRNA, QPI-1007, inhibits the expression of the caspase 2 protein and is being 
developed as a neuroprotective treatment in non-arteritic anterior ischemic optic neuropathy and glaucoma10. 
Studies using intravitreal injections of siRNAs that inhibit vascular endothelial growth factor, namely siRNA-027 
and PF-04523655, have also reached Phase I and II trials in age-related macular degeneration11,12.
Glaucoma is the leading cause of irreversible blindness and affects over 70 million people worldwide13. 
Subconjunctival fibrosis and contraction of the drainage channel created to lower intraocular pressure are the 
main causes of failure of glaucoma surgery, and human Tenon’s fibroblasts (HTFs) represent the major cell type 
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contributing to the fibrotic process. Fibrosis also plays a part in either the pathogenesis or failure of treatment of 
virtually all the blinding diseases in the world today. There is now increasing evidence that the Myocardin-related 
transcription factor/Serum response factor (MRTF/SRF) pathway plays a key role in fibroblast activation and that 
knocking down MRTF can lead to reduced scarring and fibrosis14–16. We have also recently described how the 
MRTF/ SRF pathway is intricately linked to all the key regulators and pathways in ocular fibrosis17.
Furthermore, we have previously described the use of liposome-peptide nanoparticles for both in vitro and in vivo 
gene delivery in the airway epithelium18,19, cancer20,21, and vascular tissues22,23. The liposome-peptide-siRNA nano-
particles with their synergistic lipid and peptide components can effectively package the siRNAs and protect them 
from enzymatic cleavage, can be dissociated by heparin, and are localised in the cytoplasm following transfection5,24. 
We have also developed PEGylated formulations to further increase the receptor-targeted specificity and transfection 
efficiency in cells and to enable better biocompatibility of the nanocomplexes25,26.
In this study, we have developed receptor-targeted liposome-peptide-siRNA nanoparticles as an efficient 
non-viral delivery system for MRTF-B siRNAs in human Tenon’s fibroblasts to prevent post-surgical fibrosis after 
glaucoma filtration surgery and other fibroblast-induced contractile scarring conditions in the eye.
Results
Biophysical properties of the liposome-peptide-siRNA nanoparticles. Figure 1 is a schematic 
diagram of a receptor-targeted liposome-peptide-siRNA nanoparticle prepared at a weight ratio of 1 (lipos-
ome): 4 (peptide): 1 (siRNA). All nanoparticles were strongly cationic ( + 42 to + 56 mV), with sizes around 
100 nm and polydispersity indices (PDIs) less than 0.35. The LYR (non-PEGylated liposome-peptide Y-siRNA) 
nanoparticles measured 112.5 ± 2.6 nm (SD) and the zeta potential was + 50.7 ± 0.5 mV (SD) (Fig. 2A,B). 
The LER (non-PEGylated liposome-peptide ME27-siRNA) nanoparticles measured 108.2 ± 1.7 nm (SD) and 
the zeta potential was + 54.4 ± 1.9 mV (SD). The LYR-P (PEGylated liposome-peptide Y-siRNA) nanopar-
ticles measured 122.4 ± 2.4 nm (SD) and the zeta potential was + 44.4 ± 2.0 mV (SD) (Fig. 2A,B). The LER-P 
(PEGylated liposome-peptide ME27-siRNA) nanoparticles measured 120.4 ± 1.2 nm (SD) and the zeta potential 
was + 46.3 ± 1.9 mV (SD). Negative staining transmission electron microscopy (TEM) was also used to visualise 
the nanoparticles and showed that most of the nanoparticles were spherical in morphology (Fig. 3).
Liposome-peptide-siRNA nanoparticles demonstrate high silencing efficiency in human 
Tenon’s fibroblasts. We compared the silencing efficiency of liposome-peptide-siRNA nanoparticles in 
human Tenon’s fibroblasts using different targeting peptides (Y, ME27) and different liposomes (non-PEGylated, 
PEGylated). Using 50 nM siRNA, the MRTF-B gene was efficiently silenced by 76% and 72% with LYR and LER 
nanoparticles, respectively (Fig. 4A). The expression of the MRTF-B protein was also significantly decreased 
after treatment with both LYR and LER nanoparticles (Fig. 4B,C). We have performed control experiments 
for DOTMA/DOPE/ K16/ siRNA (LKR), DOTMA/DOPE/ siRNA (LR), DOTMA/DOPE only (L), and siRNA 
only (R). The targeting formulations (LYR and LER) demonstrated better silencing efficiency than LKR, a 
non-targeting control, or LR, emphasising the importance of targeting in efficient gene silencing (Fig. 4A–C). 
There was also poor silencing efficiency when siRNA only or DOPMA/DOPE only were used, showing that deliv-
ery of naked siRNAs is not sufficient to cross the cell membrane. In addition, we found that LYR and LER nano-
particles showed higher silencing efficiency than PEGylated LYR-P and LER-P nanoparticles in human Tenon’s 
fibroblasts (Fig. 4A–C). The internalisation of the nanoparticles was also examined by confocal microscopy and 
LYR nanoparticles showed higher cellular uptake than PEGylated LYR-P nanoparticles (Supplementary Figure 1).
As LYR nanoparticles showed higher transfection efficiency, we further studied LYR nanoparticles at a higher 
siRNA concentration of 100 nM compared to 50 nM. We found that MRTF-B LYR nanoparticles efficiently 
silenced the MRTF-B gene by 76% and 80% using 50 nM and 100 nM siRNA concentrations respectively, com-
pared to 91% using lipofectamine reagent at 50 nM siRNA (Fig. 5A). The results were confirmed at protein level 
Figure 1. Schematic diagram of a receptor-targeted liposome-peptide-siRNA nanoparticle. 
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and there was a marked reduction in the MRTF-B protein expression after treatment with MRTF-B LYR nano-
particles at both 50 nM and 100 nM siRNA concentrations (Fig. 5B,C).
Liposome-peptide-siRNA nanoparticles represent a safe delivery system in the conjunc-
tiva. We next compared the cytotoxicity of the liposome-peptide-siRNA nanoparticles in human Tenon’s 
fibroblasts using different targeting peptides (Y, ME27) and different liposomes (non-PEGylated, PEGylated). 
Using 50 nM siRNA, the MRTF-B LYR and LER nanoparticles were not cytotoxic compared to control nanopar-
ticles and untreated cells (Fig. 6A). In addition, there were no statistically significant differences in cell viability 
when MRTF-B PEGylated LYR-P and LER-P were used compared to control nanoparticles and untreated cells 
(Fig. 6A).
We further compared the cytotoxicity of LYR nanoparticles in human Tenon’s fibroblasts at the higher siRNA 
concentration of 100 nM compared to 50 nM. Although the LYR nanoparticles were not cytotoxic at 50 nM 
siRNA, a decrease in cell viability was however noted with both the MRTF-B and control LYR nanoparticles at 
100 nM siRNA compared to untreated cells (Fig. 6B).
Liposome-peptide-siRNA nanoparticles prevent matrix contraction after a single transfection 
treatment. We used detached three-dimensional fibroblast-populated collagen gels as these have been shown 
to be a very good in vitro model and functional assay to study tissue contraction in the eye27,28. Figure 7A shows 
representative gel areas at day 7 of the contraction assay. The MRTF-B LYR nanoparticles effectively blocked colla-
gen matrix contraction for the whole duration of the 7-day contraction assay after a single transfection treatment, 
compared to control nanoparticles (Fig. 7B). The MRTF-B LYR nanoparticles showed the maximal inhibition in 
contraction at 50 nM siRNA compared to 100 nM siRNA.
We also noted that the fibroblasts embedded in the collagen matrix contracted less when treated with control 
nanoparticles at 100 nM siRNA compared to the fibroblasts treated with control siRNA at 50 nM (Fig. 7B). This 
decreased contractility of fibroblasts in collagen matrix could be explained by the toxic and potential off-target 
effects of the nanoparticles at 100 nM siRNA concentration. siRNAs can induce non-specific effects on pro-
tein levels that are not siRNA sequence dependent as siRNAs may cross-react with targets of limited sequence 
Figure 2. Biophysical properties of the nanoparticles with different peptide and liposome formulations. 
(A) Size in nm; (B) Zeta potential in mV.
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similarity29,30. However, siRNA off-target effects can be significantly reduced when fibroblasts are treated with a 
dose of siRNAs that is relatively low but sufficient to effectively silence the intended gene target31.
Discussion
Fibrosis remains a critical determinant of the long-term surgical success after glaucoma filtration surgery and 
small molecule therapeutics hold a lot of potential to modulate post-surgical wound healing in the eye32. In 
this study, we have developed a receptor-targeted liposome-peptide-siRNA nanoparticle incorporating MRTF-B 
siRNA. The nanocomplexes self-assemble at optimal ratios of cationic liposomes, targeting peptides and siR-
NAs, with the peptides providing siRNA packaging and cell targeting functions5,24 while the lipids help to 
modulate the surface properties of the nanoparticles, such as PEG-mediated hydrophilicity6, and assist the 
Figure 3. Negative staining transmission electron microscopy was used to visualise the nanoparticles. (A) 
LYR; (B) LER; (C) LYR-P. Most of the nanoparticles were spherical in morphology, Scale = 200 nm.
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endosomal escape within the cell after endocytosis of the nanocomplexes33,34. The MRTF-B siRNA-loaded nan-
oparticles were successfully taken up by human Tenon’s fibroblasts to deliver the therapeutic siRNAs into the 
fibroblasts. Over 70% MRTF-B gene silencing was achieved after a single transfection treatment, demonstrating 
that efficient gene silencing can be achieved by this approach. Interestingly, this level of gene silencing by the 
liposome-peptide-siRNA nanoparticles in human Tenon’s fibroblasts was also effective to completely block matrix 
contraction for the whole duration of the 7-day functional contraction assay.
Nanotechnology and nanoparticles currently represent an area of great research interest due to the trans-
lational potential in a wide variety of scientific fields. Our next aim is to validate our results in vivo by testing 
the different nanoparticle formulations in the rabbit model of glaucoma filtration surgery. The rabbit model of 
glaucoma filtration surgery represents a very aggressive scarring response compared to that in humans35,36. It is 
a well-established model of ocular fibrosis and agents that have reduced scarring in the rabbit have been shown 
to be effective in humans in clinical trials37–39. Butler et al. have reported that topical silver nanoparticles led to a 
sustained reduction in intraocular pressure and blebs with decreased fibrosis and ischaemia in the rabbit model 
of glaucoma filtration surgery40. Furthermore, Ye et al. have tested subconjunctival injections of nano-copolymers 
[CS-g-(PEI-b-mPEG)/ IKKβ -siRNA] in a non-human primate model of glaucoma filtration surgery and found a 
significant improvement in the bleb survival and subconjunctival scarring compared to controls41.
Size and charge play a key role on the cellular uptake and cytotoxicity of nanoparticles. Several authors 
have shown an inverse relationship between size and cytotoxicity42–46 or cellular uptake42,47–51 of nanoparticles. 
Bhattacharjee et al. have reported that positive smaller polymer nanoparticles (45 nm) showed higher cellular 
uptake but higher cytotoxicity than positive bigger nanoparticles (90 nm)42. Possible mechanisms for the higher 
toxicity might be a reduction in mitochondrial membrane potential, uncoupling of the electron transfer chain 
in mitochondria and resulting ATP production, induction of reactive oxygen species and oxidative stress42. 
Zhang et al. have also performed a molecular modeling and thermodynamics study and have predicted higher 
cellular uptake for nanoparticles of about 44 nm in size51, due to stronger interactions with the receptors in 
receptor-mediated endocytosis. In this study, we have used positive receptor-targeted liposome-peptide-siRNA 
nanoparticles of about 100 nm and they have shown high silencing efficiency with the use of targeting peptides 
as well as low cytotoxicity.
Figure 4. Silencing efficiency of the liposome-peptide-siRNA nanoparticles with different peptide and 
liposome formulations. (A) Using 50 nM siRNA, the MRTF-B gene was efficiently silenced by 76% and 72% 
with LYR and LER nanoparticles, respectively. LYR and LER nanoparticles showed higher silencing efficiency 
than PEGylated LYR-P and LER-P nanoparticles. mRNA levels were normalised relative to GAPDH and the 
results shown are mean ± SD for triplicate experiments; (B) Western blotting showed a significant decrease in 
the MRTF-B protein expression with LYR and LER nanoparticles; (C) MRTF-B protein silencing was calculated 
using densitometric analysis and GAPDH as loading control.
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Figure 5. Silencing efficiency of LYR nanoparticles with different siRNA concentrations. (A) The expression 
of the MRTF-B gene was efficiently silenced by 76% and 80% at 50 nM and 100 nM siRNA respectively, 
compared to the 91% achieved using lipofectamine reagent at 50 nM siRNA; (B) Western blotting also showed a 
marked reduction in the MRTF-B protein levels after treatment with MRTF-B LYR nanoparticles at both 50 nM 
and 100 nM siRNA; (C) MRTF-B protein silencing was calculated using densitometric analysis and GAPDH as 
loading control.
Figure 6. Cytotoxicity of nanoparticles. (A) Using 50 nM siRNA, MRTF-B nanoparticles with different 
targeting peptides and liposomes (LYR, LER, LYR-P, LER-P) did not significantly affect cell viability compared 
to control nanoparticles and untreated cells; (B) A decrease in cell viability was however noted with both 
MRTF-B and control LYR nanoparticles at 100 nM siRNA compared to untreated cells. Results shown are 
mean ± SD for six independent replicates.
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Receptor-targeted delivery systems, using targeting peptides and ligands, have the key advantage of facil-
itating uptake into target cells and of preventing non-specific delivery into normal tissues52. In our study, 
receptor-targeted liposome-peptide-siRNA nanoparticles efficiently silenced the MRTF-B gene by 76% and 
72% in human Tenon’s fibroblasts using the targeting peptides Y and ME27, respectively. Both peptides cyclise 
rapidly after dissolving by oxidation as we have previously described for a similar peptide53. ME27 contains a 
tripeptide Arg-Gly-Asp (RGD) motif that targets integrins, particularly α vβ 3, α vβ 5, and α 5β 1, and these surface 
integrin receptors are abundantly expressed on human eye fibroblasts54. The peptide ligand YGLPHKF in pep-
tide Y has been identified by biopanning a phage peptide library. Peptide Y closely resembles part of a targeting 
protein expressed by the intracellular pathogen Legionella pneumophila5,22 but the identity of the receptor is still 
unknown55. However, we have shown that peptide Y mediates the targeted delivery of siRNA in nanocomplexes 
to cells of neuronal origin5,24, lung cells6,26, primary vascular cells and rabbit aorta22,23, and is thus a peptide that 
could be used for different target tissues.
In addition, our study shows that non-PEGylated liposome formulations have higher silencing efficiency than 
PEGylated liposome formulations in human Tenon’s fibroblasts. Stealth coatings of nanocomplexes, for example 
by PEGylation, can enhance serum stability and minimise non-specific interactions, but can also affect cellular 
uptake and thus decrease the transfection efficiency of nanocomplexes56,57. The PEGylated nanoparticles in this 
study were slightly bigger in size than the non-PEGylated ones and also less cationic due possibly to PEG shield-
ing, and these biophysical differences in conjunction with the lower cellular uptake might have contributed to the 
observed reduced silencing effect. Another potential reason could be that the peptide was not able to reach its cell 
target due to PEG shielding. However, since the PEGylation was performed in exactly the same way during the 
liposomal preparation as in our previously published work which showed high targeting specificity for anionic 
nanocomplexes with the same PEG moiety6,25, we did not anticipate that this would play a crucial role.
Toxicity is another major hurdle to overcome when developing new anti-fibrotic treatments in the eye. 
Lipofectamine is a very efficient transfection reagent but is however cytotoxic and cannot be used in vivo and in 
the eye58,59. The liposome-peptide-siRNA nanoparticles were not cytotoxic in human Tenon’s fibroblasts at 50 nM 
siRNA concentration, supporting their safety as a non-viral siRNA delivery system to the conjunctiva. Higher 
siRNA concentrations, e.g. 100 nM, however showed a decrease in cell viability compared to the untreated cells. 
In addition, nanoparticles using different targeting peptides (Y, ME27) and different liposomes (non-PEGylated, 
PEGylated) did not significantly affect cell viability compared to control nanoparticles and untreated cells. 
Ladewig et al. have shown that layered double hydroxide nanoparticles facilitated uptake of siRNAs into mamma-
lian cells due to their small size (100 nm) and positive charge, and also showed low cytotoxicity60. However, large 
particle sizes and higher concentrations have been associated with increased cytotoxicity and genotoxicity61. Tan 
et al. did not observe any toxic side effects with the layer-by-layer nanoparticles62, and Ye et al. have also found 
that the cationic nano-copolymers were well tolerated in the eye41.
In conclusion, we have developed a receptor-targeted liposome-peptide-siRNA nanoparticle incorpo-
rating MRTF-B siRNA, targeting peptides, and cationic liposomes. The MRTF-B siRNA-loaded nanoparti-
cles efficiently silenced the expression of the MRTF-B gene in human Tenon’s fibroblasts, were not cytotoxic, 
and completely blocked collagen matrix contraction after a single transfection treatment. Receptor-targeted 
Figure 7. The MRTF-B LYR nanoparticles prevented collagen matrix contraction after a single transfection 
treatment compared to control LYR nanoparticles. (A) Representative gel areas at day 7 of contraction assay;  
(B) The MRTF-B LYR nanoparticles showed the maximal decrease in matrix contraction at 50 nM siRNA 
compared to 100 nM siRNA.
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liposome-peptide-siRNA nanoparticles thus represent an efficient and safe non-viral siRNA delivery system that 
could be used to prevent conjunctival fibrosis after glaucoma filtration surgery and other fibroblast-induced con-
tractile scarring conditions in the eye.
Methods
Cell Culture. Primary human Tenon’s fibroblasts (HTFs) were isolated from donor eyes in the eye bank and 
informed consent was obtained from all subjects. All experimental protocols were approved by the institutional 
approval committee at the University College London Institute of Ophthalmology, and all the methods were 
carried out in accordance with the approved guidelines. Cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM, Invitrogen) with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 mg/ml streptomycin, 
and 2 nM L-glutamine, in tissue culture incubators with 5% CO2 and 95% humidity. Cells between passages 2–8 
were used in the experiments.
Preparation of Nanoparticle formulations. The liposome-peptide-siRNA nanoparticle formulations 
were prepared at a weight ratio of 1 (liposome): 4 (peptide): 1 (siRNA), by first mixing the liposome (0.2 mg/ml 
in water) with the peptide (0.2 mg/ml in OptiMEM [Life Technologies, UK]), followed by the addition of siRNA 
(5 μ M stock diluted in OptiMEM). The mixture was incubated at room temperature for one hour to allow com-
plex formation, and then additional OptiMEM was included to give a final siRNA concentration of 50 nM or 
100 nM. Different targeting peptides (Y, ME27) and different liposomes (non-PEGylated, PEGylated) were used 
to prepare the nanoparticle formulations. The structures of the different lipids and peptides are shown in Table 1. 
The non-PEGylated liposomes were made up of DOTMA/DOPE (1:1 molar ratio), and the PEGylated liposomes 
were made up of 47.5% DOTMA: 47.5% DOPE: 5% DPPE-PEG2000 in molar ratios. All the lipids were bought 
from Avanti polar lipids (Alabama, USA) and all the peptides were synthesised by ChinaPeptides (Shanghai, 
China). The nanoparticle formulations were also compared to lipofectamine reagent [Life Technologies, UK] 
using 50 nM siRNA and according to the manufacturer’s instructions.
HTFs were seeded at 1 × 105 cells/well in 6-well plates (Falcon, Fisher Scientific UK) and incubated for 
24 hours before the nanocomplexes were added. HTFs were incubated with the nanoparticle complexes in 
OptiMEM for 4 hours at 37 °C. Following the 4 hour incubation, the medium containing the nanoparticles was 
replaced by fresh growth medium and the cells were incubated for a further 48 hours at 37 °C. HTFs were then 
used for RNA extraction to measure the silencing efficiency by real-time qPCR, or lysed to detect the silencing at 
protein level by western blotting.
Nanoparticle size, zeta potential measurements, morphology, and internalisation of siRNA 
complexes. Nanoparticle size and zeta potential were determined by dynamic light scattering and by laser 
Doppler anemometry respectively, using a Nano ZS Zetasizer (Malvern Instruments, Malvern, UK) with the fol-
lowing specifications: automatic sampling time of 10 measurements/ sample, refractive index of 1.330, dielectric 
constant 78.5, viscosity 0.8872 cP, and temperature of 25 °C. Zeta potential settings were calibrated against the 
standard (− 68 mV ± 6.8 mV). Triplicate measurements were performed for each sample and the results were 
analysed using the software provided by the manufacturer (DTS version 5.03). The nanoparticles were also visual-
ised using negative staining transmission electron microscopy (TEM) to study their morphology as previously 
described26.
1.5 × 105 cells were seeded onto poly-L-lysine coated slides (SLS, Dublin, Ireland). The following day they were 
transfected with Cy3-labelled GAPDH siRNA (final concentration of siRNA was 200 nM; Applied Biosystems, 
Warrington, UK) complexed with our formulations made as described above in triplicates. After 4 hours of incu-
bation, the slides were washed with phosphate-buffered saline (PBS) and fixed in 4% formaldehyde, permeabi-
lised with 0.5% Triton, and stained for 45 minutes with AlexaFluor 488 phalloidin (1:200, Invitrogen, Paisley, 
UK). The slides were then washed and sealed in mounting media containing DAPI (Invitrogen, Paisley, UK), and 
Lipids Chemical Name Structure
DOPE 1,2-dioleoyl-sn-glycero- 3-phosphoethanolamine
DOTMA 1,2-di-O-octadecenyl- 3-trimethylammonium propane
DPPE-PEG2000
1,2-dipalmitoyl-sn-glycero-
3-phosphoethanolamine-
N-[methoxy(polyethylene 
glycol)-2000]
Peptides Chemical Name Structure
Targeting Y K16GACYGLPHKFCG
Targeting ME27 K16RVRRGACRGDCLG
Table 1. Structures of the different lipids and peptides.
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imaged at a magnification of x400 on a Carl Zeiss LSM710 laser scanning microscope system (Jena, Germany) as 
previously described24.
Small interfering RNA Transfection. MRTF-B was knocked down using a SMARTpool of siGENOME 
human MRTF-B siRNAs (Dharmacon), with the following target sequences: GAAAAGAGCUCGACUAGCA, 
GAACGAGCCAGAACUGAAA, GGAUGGAACUUUACCCUCA, UCAGAAGGGUGAGAAGAAU. HTFs 
were transfected with 50 nM or 100 nM of MRTF-B siRNAs or control siRNAs (AllStars Negative Control siR-
NAs, Qiagen).
MTT Cell Assay. Cell viability was measured using the Vybrant® MTT Assay (Life Technologies, UK). 
HTFs were seeded in 96-well plates and transfected with liposome-peptide-siRNA nanoparticles as described 
above. After 48 hours, the nanoparticle complexes were replaced by fresh growth medium. 10 μ l of the 12 mM 
MTT solution [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] were added to each well and 
incubated for 4 hours at 37 °C. After 4 hours, 50 μ l of DMSO were added to each well and incubated for a fur-
ther 10 minutes at 37 °C. Each experiment was carried out with six independent replicates for each condi-
tion. Absorbance was measured at 540 nm on a SpectraMax Plus 384 spectrophotometer (Molecular Devices, 
California, USA).
Real-Time Quantitative PCR. HTFs were lysed for RNA extraction using the Sigma RNA isolation kit 
(Sigma-Aldrich, Dorset, UK) according to the manufacturer’s instructions. Reverse transcription was carried 
out using the Transcriptor First Strand cDNA Synthesis Kit (Roche) according to the manufacturer’s instruc-
tions. RT-qPCR reactions were performed using SYBR green reagents (Life Technologies) on an HT7900 Fast 
Real-Time PCR system (Applied Biosystems, Life Technologies). The primer sequences for MRTF-B and GAPDH 
are listed in Table 2. All mRNA values were normalised relative to that of GAPDH and a standard curve using 
human genomic DNA was used to quantify the mRNA levels for each condition. Each experiment was carried out 
as independent triplicates for each group.
Western Blotting. Proteins were extracted from HTFs using 2 × SDS sample buffer (100 mM Tris HCL pH 
6.8, 4% SDS, 20% glycerol, 200 mM dithiothreitol and 0.2% bromophenol blue). Equal amounts of protein were 
loaded onto and run on 4–12% NuPAGE Bis-Tris protein gels (Novex, Life Technologies). The gels were trans-
ferred onto nitrocellulose blotting membranes (Amersham, Life Sciences), and blocked in 3% non-fat milk in 
PBST (PBS 0.1% Tween) for 60 minutes. The membranes were then incubated overnight at 4 °C in primary anti-
body (MRTF-B, C-19 sc-47282, 1:1000, Santa Cruz; GAPDH, G9545, 1:3000, Sigma). The next day, the mem-
branes were washed three times for 10 minutes each in PBST, and incubated for 1 hour at room temperature in 
secondary-labelled antibody (MRTF-B: Anti-goat HRP immunoglobulins, 1:2000, Dako; GAPDH: Anti-rabbit 
HRP immunoglobulins, 1:5000, Dako). The membranes were then washed with PBST three times for 10 minutes 
each, treated with ECL solution (Amersham, Life sciences) for 5 minutes, and scanned on an Odyssey IR Imager 
(LI-COR). MRTF-B protein silencing was also measured using densitometric analysis and GAPDH as loading 
control.
Collagen Contraction Assays. HTFs were trypsinised and a cell suspension containing 1 × 105 cells/ml 
was centrifuged at 1500 rpm for 5 minutes. The supernatant was aspirated and the cell pellet re-suspended in 
100 μ l of fetal calf serum. A collagen gel solution was prepared using 1 ml of Type I collagen (2.05 mg/ml in 0.6% 
acetic acid, First Link) and 160 μ l of concentrated medium (1.4 mls DMEM [Sigma Aldrich], 140 μ l L-glutamine 
[Life Technologies], 360 μ l sodium bicarbonate 7.5% [Sigma Aldrich]). The collagen solution was rapidly adjusted 
to pH 7 with sodium hydroxide and the cells were then added to the collagen solution. The fibroblast-populated 
collagen gel mixture was quickly cast into the wells of Mat Tek dishes (MatTek Corp, MI, USA), and left to set in 
the incubator for 10 minutes. Each gel was then detached from the edges of the well and put back into the incuba-
tor with 2 ml of growth medium. Whole matrix contraction was measured using digital images taken immediately 
following release of the polymerised matrices (t0) and then daily for 7 days (tn). The images were imported into 
Image J software (http://rsb.info.nih.gov/ij/). Gel surface area was normalised to the area calculated at t0 using the 
following formula: A (tn) in % = 100 − (100 × rtn2/rto2), where A is the gel surface area and r is the radius. Each 
experiment was performed as triplicates of matrices for each condition.
Statistical Analysis. All graphs display mean and standard deviation (SD). Statistical analysis was per-
formed using the Student’s t-test to calculate statistically significant differences and individual P values. 
Statistically significant differences were expressed as *P < 0.05, **P < 0.01.
Primers Sequences
MRTF-B
F CTTCCTGTGGACTCCAGTG
R TGTGACTCCTGACTCGCAG
GAPDH
F GAAATGTGCTTTGGGGAGGC
R GGGGACAGGACCATATTGAGG
Table 2. List of primers and their sequences.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:21881 | DOI: 10.1038/srep21881
References
1. Yin, H. et al. Non-viral vectors for gene-based therapy. Nature Rev Genet 15, 541–555 (2014).
2. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498 
(2001).
3. Borel, F., Kay, M. A. & Mueller, C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol 
Ther. 22, 692–701 (2014).
4. Kang, E. M. & Tisdale, J. F. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy 
applications. Curr Hematol Rep 3, 274–281 (2004).
5. Tagalakis, A. D., He, L., Saraiva, L., Gustafsson, K. T. & Hart, S. L. Receptor-targeted liposome-peptide nanocomplexes for siRNA 
delivery. Biomaterials 32, 6302–6315 (2011).
6. Tagalakis, A. D. et al. Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery. 
Biomaterials 35, 8406–8415 (2014).
7. Kim, B. et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes - therapeutic 
strategy for herpetic stromal keratitis. Am J Pathol 165, 2177–2185 (2004).
8. Jia, R. B. et al. VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res. 39, 
108–115 (2007).
9. Nakamura, H. et al. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation 
and fibrosis. Mol Vis 10, 703–711 (2004).
10. Solano, E. C. et al. Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting 
caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 24, 258–266 (2014).
11. Nguyen, Q. D. et al. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular 
degeneration (MONET Study). Ophthalmology 119, 1867–1873 (2012).
12. Kaiser, P. K. et al. RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027. Am J Ophthalmol 150, 
33–39 (2010).
13. Quigley, H. A. Glaucoma. Lancet 377, 1367–1377 (2011).
14. Small, E. M. et al. Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial 
infarction. Circ Res 107, 294–304 (2010).
15. Luchsinger, L. L., Patenaude, C. A., Smith, B. D. & Layne, M. D. Myocardin-related transcription factor-A complexes activate type I 
collagen expression in lung fibroblasts. J Biol Chem 286, 44116–44125 (2011).
16. Minami, T. et al. Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice. EMBO 
J 31, 4428–4440 (2012).
17. Yu-Wai-Man, C., Treisman, R. T., Bailly, M. & Khaw, P. T. The role of the MRTF-A/ SRF pathway in Ocular fibrosis. Invest 
Ophthalmol Vis Sci. 55, 4560–4567 (2014).
18. Manunta, M. D. et al. Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium. PLoS ONE 6, 
e26768 (2011).
19. Tagalakis, A. D. et al. A receptor-targeted nanocomplex vector system optimized for respiratory gene transfer. Mol. Ther. 16, 907–915 
(2008).
20. Kenny, G. D. et al. Multifunctional receptor-targeted nanocomplexes for magnetic resonance imaging and transfection of tumours. 
Biomaterials 33, 7241–7250 (2012).
21. Tagalakis, A. D. et al. Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration. 
Biomaterials 32, 1370–1376 (2011).
22. Irvine, S. A. et al. Receptor-targeted nanocomplexes optimized for gene transfer to primary vascular cells and explant cultures of 
rabbit aorta. Mol. Ther. 16, 508–515 (2008).
23. Meng, Q. H. et al. Inhibition of neointimal hyperplasia in a rabbit vein graft model following non-viral transfection with human 
iNOS cDNA. Gene Ther. 20, 979–986 (2013).
24. Tagalakis, A. D., Saraiva, L., McCarthy, D., Gustafsson, K. T. & Hart, S. L. Comparison of nanocomplexes with branched and linear 
peptides for siRNA delivery. Biomacromolecules 14, 761–770 (2013).
25. Tagalakis, A. D. et al. PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, 
anionic nanocomplexes. J Control Release 174, 177–187 (2014).
26. Tagalakis, A. D. et al. A method for concentrating lipid peptide DNA and siRNA nanocomplexes that retains their structure and 
transfection efficiency. Int J Nanomedicine 10, 2673–2683 (2015).
27. Dahlmann-Noor, A. H., Martin-Martin, B., Eastwood, M., Khaw, P. T. & Bailly, M. Dynamic protrusive cell behaviour generates 
force and drives early matrix contraction by fibroblasts. Exp Cell Res 313, 4158–4169 (2007).
28. Daniels, J. T. et al. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production 
in vitro. Invest Ophthalmol Vis Sci. 44, 1104–1110 (2003).
29. Jackson, A. L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 21, 635–637 (2003).
30. Scacheri, P. C. et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in 
mammalian cells. Proc Natl Acad Sci USA 101, 1892–1897 (2004).
31. Caffrey, D. R. et al. siRNA Off-Target Effects Can Be Reduced at Concentrations That Match Their Individual Potency. PLoS ONE. 
6, e21503 (2011).
32. Yu-Wai-Man, C. & Khaw, P. T. Developing novel anti-fibrotic therapeutics to modulate post-surgical wound healing in glaucoma: 
Big potential for small molecules. Expert Rev Ophthalmol. 10, 65–76 (2015).
33. Du, Z., Munye, M. M., Tagalakis, A. D., Manunta, M. D. & Hart, S. L. The role of the helper lipid on the DNA transfection efficiency 
of lipopolyplex formulations. Sci Rep 4, 7107 (2014).
34. Munye, M. M. et al. Role of liposome and peptide in the synergistic enhancement of transfection with a lipopolyplex vector. Sci Rep 
5, 9292 (2015).
35. Wong, T. T. L., Mead, A. L. & Khaw, P. T. Matrix Metalloproteinase Inhibition Modulates Postoperative Scarring after Experimental 
Glaucoma Filtration Surgery. Invest Ophthalmol Vis Sci. 44, 1097–1103 (2003).
36. Cordeiro, M. F., Gay, J. & Khaw, P. T. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. 
Invest Ophthalmol Vis Sci 40, 2225–2234 (1999).
37. Khaw, P. T., Doyle, J. W., Sherwood, M. B., Smith, M. F. & McGorray, S. Effects of intraoperative 5-fluorouracil or mitomycin C on 
glaucoma filtration surgery in the rabbit. Ophthalmology 100, 367–372 (1993).
38. Yorston, D. & Khaw, P. T. A randomised trial of the effect of intraoperative 5-FU on the outcome of trabeculectomy in east Africa. Br 
J Ophthalmol 85, 1028–1030 (2001).
39. Lanigan, L., Stürmer, J., Baez, K. A., Hitchings, R. A. & Khaw, P. T. Single intraoperative applications of 5-fluorouracil during 
filtration surgery: early results. Br J Ophthalmol 78, 33–37 (1994).
40. Butler, M. R. et al. Topical silver nanoparticles result in improved bleb function by increasing filtration and reducing fibrosis in a 
rabbit model of filtration surgery. Invest Ophthalmol Vis Sci. 54, 4982–4990 (2013).
41. Ye, H. et al. Cationic nano-copolymers mediated IKKβ targeting siRNA to modulate wound healing in a monkey model of glaucoma 
filtration surgery. Mol Vis. 16, 2502–2510 (2010).
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:21881 | DOI: 10.1038/srep21881
42. Bhattacharjee, S. et al. Surface charge-specific cytotoxicity and cellular uptake of tri-block copolymer nanoparticles. Nanotoxicology. 
7, 71–84 (2013).
43. Pan, Y. et al. Size-dependent cytotoxicity of gold nanoparticles. Small. 3, 1941–1949 (2007).
44. Carlson, C. et al. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys 
Chem B. 112, 13608–13619 (2008).
45. Yu, K. O. et al. Toxicity of amorphous silica nanoparticles in mouse keratinocytes. J Nanopart Res. 11, 15–24 (2009).
46. Prabhu, B. M., Ali, S. F., Murdock, R. C., Hussain, S. M. & Srivatsan, M. Copper nanoparticles exert size and concentration 
dependent toxicity on somatosensory neurons of rat. Nanotoxicology. 4, 150–160 (2010).
47. Win, K. Y. & Feng, S. S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of 
anticancer drugs. Biomaterials. 26, 2713–2722 (2005).
48. Johnston, H. J. et al. Evaluating the uptake and intracellular fate of polystyrene nanoparticles by primary and hepatocyte cell lines 
in vitro. Toxicol Appl Pharmacol. 242, 66–78 (2010).
49. Foged, C., Brodin, B., Frokjaer, S. & Sundblad, A. Particle size and surface charge affect particle uptake by human dendritic cells in 
an in vitro model. Int J Pharm. 298, 315–322 (2005).
50. Oh, W.-K. et al. Cellular uptake, cytotoxicity, and innate immune response of silica-titania hollow nanoparticles based on size and 
surface functionality. ACS Nano. 4, 5301–5313 (2010).
51. Zhang, S. L., Li, J., Lykotrafitis, G., Bao, G. & Suresh, S. Size-dependent endocytosis of nanoparticles. Adv Mater. 21, 419–424 (2009).
52. Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8, 
129–138 (2009).
53. Hart, S. L., Collins, L., Gustafsson, K. & Fabre, J. W. Integrin-mediated transfection with peptides containing arginine-glycine-
aspartic acid domains. Gene Therapy 4, 1225–1230 (1997).
54. Masur, S. K., Cheung, J. K. H. & Antohi, S. Identification of Integrins in Cultured Corneal Fibroblasts and in Isolated Keratocytes. 
Invest Ophthalmol Vis Sci 34, 2690–2698 (1993).
55. Writer, M. J. et al. Targeted gene delivery to human airway epithelial cells with synthetic vectors incorporating novel targeting 
peptides selected by phage display. J Drug Target 12, 185–193 (2004).
56. Huang, F. W. et al. PEGylated PEI-based biodegradable polymers as non-viral gene vectors. Acta Biomater. 6, 4285–4295 (2010).
57. Mishra, S., Webster, P. & Davis, M. E. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene 
delivery particles. Eur J Cell Biol. 83, 97–111 (2004).
58. Jere, D. et al. Poly (amino ester) composed of poly (ethylene glycol) and aminosilane prepared by combinatorial chemistry as a gene 
carrier. Pharm Res. 25, 875–885 (2008).
59. Corsi, K., Chellat, F., Yahia, L. & Fernandes, J. C. Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA 
nanoparticles. Biomaterials 24, 1255–1264 (2003).
60. Ladewig, K., Niebert, M., Xu, Z. P., Gray, P. P. & Lu, G. Q. Efficient siRNA delivery to mammalian cells using layered double 
hydroxide nanoparticles. Biomaterials 31, 1821–1829 (2010).
61. Lee, K. J. et al. In vivo quantitative study of sized-dependent transport and toxicity of single silver nanoparticles using zebrafish 
embryos. Chem Res Toxicol. 25, 1029–1046 (2012).
62. Tan, Y. F. et al. Layer-by-layer nanoparticles as an efficient siRNA delivery vehicle for SPARC silencing. Small 10, 1790–1798 (2014).
Acknowledgements
CY is funded by an NIHR BRC Francis Crick Institute Clinical Research Training Fellowship. Our research is 
supported by the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital 
NHS Foundation Trust and UCL Institute of Ophthalmology (NIHR BRC), the Medical Research Council, 
Moorfields Trustees and Moorfields Eye Charity, the Freemasons Grand Charity, the Michael and Ilse Katz 
Foundation, the Helen Hamlyn Trust, and Fight for Sight.
Author Contributions
C.Y., A.T., M.M. designed and performed the experiments, analysed the data, and prepared the manuscript. P.T.K. 
and S.L.H. designed the study and supervised the project. All authors discussed the results and commented on 
the manuscript.
Additional Information
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Yu-Wai-Man, C. et al. Receptor-targeted liposome-peptide-siRNA nanoparticles 
represent an efficient delivery system for MRTF silencing in conjunctival fibrosis. Sci. Rep. 6, 21881; doi: 
10.1038/srep21881 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
